AI Article Synopsis

  • A predictive model for advanced fibrosis in chronic hepatitis B (CHB) patients was developed using serum biomarkers from a group of 249 patients, split into a training group (125) and a validation group (124).
  • Key predictors identified included gamma-glutamyl transpeptidase (GGT), platelet count, Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA-M2BP), and hyaluronic acid, which were utilized to generate the GMPH score formula for assessing fibrosis levels.
  • The GMPH score showed the best predictive accuracy for advanced fibrosis, achieving an AUROC of 0.8064 in the training group and 0.7782 in the validation group

Article Abstract

We created a predictive model using serum-based biomarkers for advanced fibrosis (F3 or more) in patients with chronic hepatitis B (CHB) and to confirm the accuracy in an independent cohort.A total of 249 CHB patients were analyzed. To achieve our study aim, a training group (n = 125) and a validation group (n = 124) were formed. In the training group, parameters related to the presence of advanced fibrosis in univariate and multivariate analyses were examined, and a formula for advanced fibrosis was created. Next, we verified the applicability of the predictive model in the validation group.Multivariate analysis identified that gamma-glutamyl transpeptidase (GGT, P = 0.0343) and platelet count (P = 0.0034) were significant predictors of the presence of advanced fibrosis, while Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA-M2BP, P = 0.0741) and hyaluronic acid (P = 0.0916) tended to be significant factors. Using these 4 parameters, we created the following formula: GMPH score = -0.755 - (0.015 × GGT) - (0.268 × WFA-M2BP) + (0.167 × platelet count) + (0.003 × hyaluronic acid). In 8 analyzed variables (WFA-M2BP, aspartate aminotransferase-to-platelet ratio index, FIB-4 index, prothrombin time, platelet count, hyaluronic acid, Forns index, and GMPH score), GMPH score had the highest area under the receiver operating characteristic (AUROC) curve for advanced fibrosis with a value of 0.8064 in the training group and in the validation group, GMPH score also had the highest AUROC (0.7782). In all subgroup analyses of the hepatitis B virus (HBV) status (HB surface antigen quantification, HBV-DNA quantification, and HBe antigen seropositivity), GMPH score in F3 or F4 was significantly lower than that in F0 to F2. In the above mentioned 8 variables, differences between the liver fibrosis stages (F0 to F1 vs F2, F2 vs F3, F3 vs F4, F0 to F1 vs F3, F0 to F1 vs F4, and F2 vs F4) for the entire cohort (n = 249) were all significant only in GMPH score.In conclusion, the GMPH scoring system may be helpful for detecting advanced liver fibrosis in patients with CHB.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008579PMC
http://dx.doi.org/10.1097/MD.0000000000004679DOI Listing

Publication Analysis

Top Keywords

advanced fibrosis
24
gmph score
16
predictive model
12
fibrosis patients
12
training group
12
fibrosis
8
patients chronic
8
chronic hepatitis
8
validation group
8
presence advanced
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!